T80.311A ABO incompatibility with delayed hemolytic transfusion reaction, initial encounter

Name of the Condition

• ABO incompatibility with delayed hemolytic transfusion reaction, initial encounter.

Summary

This condition describes an adverse immune reaction that occurs when blood or blood products with incompatible ABO antigens are transfused, leading to delayed hemolysis (destruction of red blood cells). It is a serious complication that can cause systemic effects, including organ damage and hemodynamic instability. The reaction is driven by pre-existing antibodies in the recipient that target antigens on the transfused red blood cells, and "initial encounter" indicates the first episode of care for this reaction.

Causes

ABO incompatibility reactions result from the transfusion of blood or blood products containing ABO antigens that do not match the recipient's blood type. This mismatch triggers an immune response, where the recipient's antibodies bind to the donor red blood cells, leading to their destruction (hemolysis). The reaction can occur with red blood cells, plasma, or platelets if ABO compatibility is not maintained.

Risk Factors

• Transfusion of blood products without proper ABO typing or crossmatching
• Emergency transfusions where typing may be delayed
• Human error in blood product labeling or administration
• Use of pooled plasma products with mixed ABO types
• Transfusion of platelets or plasma from donors with incompatible ABO antigens

Symptoms

• Fever, chills, or rigors
• Flank pain or back pain
• Hemoglobinuria (dark urine)
• Jaundice
• Unexplained anemia
• Elevated bilirubin levels

Diagnosis

Diagnosis involves clinical evaluation of symptoms, laboratory tests to detect hemolysis (e.g., elevated lactate dehydrogenase, decreased haptoglobin, increased indirect bilirubin), and confirmation of ABO incompatibility through blood typing and crossmatching. The delayed nature of the reaction may require retrospective review of transfusion records and antibody screening.

Treatment Options

Treatment focuses on managing hemolysis and preventing complications. This may include discontinuing the transfusion, administering intravenous fluids, and monitoring for renal function. In severe cases, supportive care for organ dysfunction or hemodynamic instability may be required. Corticosteroids or other immunosuppressants are not typically used unless additional immune-mediated reactions are present.

Prognosis and Follow-Up

Prognosis depends on the severity of hemolysis and organ involvement. Most patients recover with appropriate management, but delayed reactions can lead to complications like acute kidney injury. Follow-up includes monitoring hemoglobin levels, renal function, and resolution of symptoms. Long-term surveillance may be needed if organ damage occurs.

Complications

• Acute kidney injury
• Disseminated intravascular coagulation (DIC)
• Hypotension or shock
• Multi-organ failure
• Death (in severe cases)

Lifestyle & Prevention

Prevention relies on strict adherence to blood typing and crossmatching protocols before transfusion. Patients should inform healthcare providers of any previous transfusion reactions. Avoiding unnecessary transfusions and using leukoreduced products may reduce risk. Education on transfusion safety for healthcare staff is critical.

When to Seek Professional Help

Seek immediate medical attention if symptoms of hemolysis (e.g., dark urine, jaundice, fever) occur after a transfusion. Prompt evaluation is necessary to confirm the reaction and initiate treatment to prevent complications.

Tips for Medical Coders

Document the timing of the reaction (delayed) and specify it is the initial encounter. Include details of the transfusion event, blood product type, and confirmation of ABO incompatibility. Ensure clinical documentation supports the diagnosis and encounter type to justify code assignment.